Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

Supreme Court shuts another door on patent settlement agreement antitrust challenge – denies certiorari in Cipro case: Louisiana Wholesale Drug Co. v. Bayer AG (FDA Law Blog) (Patent Docs)

Melatonin – EWCA refers SPC questions to the ECJ: Neurim Pharmaceuticals (1991) Ltd v Comptroller General of Patents (The SPC Blog) (The SPC Blog) (EPLAW) (IPKat)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

New IP resource for Pharma, Biotech and Chem – Licensing and listing (IP Think Tank)

Genetics company Myriad may shift from patent to proprietary data (IP Watch)

WHO Working Group gives guidelines to fight bad medicines; IMPACT in exile (IP Watch)

Comments on incentivizing humanitarian technologies and licensing through the intellectual property system (KEI)

Patent woes threaten drug firms (Patently-O) (IPBiz)

Australia: Senate submissions overwhelmingly oppose ‘gene patent’ ban (Patentology)

Brazil: Court ruling could speed pharma patent process in Brazil (Patent Baristas)

Brazil: Intervention of Brazil to the WTO TRIPS Council (March 2011) providing details about the Brazilian HIV treatment program (KEI)

Hungary: Burden of proof of oral disclosure (EPLAW)

India: Domestic pharma says ‘yes’ to data exclusivity? (Spicy IP)

Malta: ‘They shall not pass’ – Maltese court hands down decision in a cross-border seizure case (regarding trade marked pharmaceuticals) against defendant (IPKat)

Peru: PIIPA helps get to the root of maca biopiracy (IP tango)

US: IP position critical to biotech investment (PatentlyBIOtech)

US: Schering files for PTA calculation correction in respect of patent covering ‘Thrombin receptor antagonists’ (Patent Docs)

US: Cellectis files patent infringement complaint based on Precision’s use of Directed Nuclease Editor technology in Delaware; Precision files for declaratory judgement of non-infringement and invalidity in ED North Carolina (Patent Docs)

US: Novozymes Ethanol enzyme patent (barely) survives summary judgment: Novozymes v Danisco (Green Patent Blog)

US: District Court S D New York: Surviving summary judgment insulates against request for attorneys’ fees: Astrazeneca v Laboratorios Dr Esteve et al (Docket Report)

Products

Cancidas (Caspofungin) – US: Merck and Teva settle patent dispute over Cancidas (Patent Docs)

Cervarix, Gardasil – EU: Queensland questions on products protected by basic patents for ECJ: Case C-630/10 University of Queensland, CSL Ltd v Comptroller-General of Patents, Designs and Trade Marks (The SPC Blog)

Cipro (Ciprofloxacin) – US: Supreme Court shuts another door on patent settlement agreement antitrust challenge – denies certiorari in Cipro case: Louisiana Wholesale Drug Co. v. Bayer AG  (FDA Law Blog) (Patent Docs)

Dexilant (Dexlansoprazole) – US: Takeda files patent infringement suit against Handa following Para IV certification filing (Patent Docs)

EpiPen – US: Orange Book patent delisting counterclaim raised in 505(b)(2) application patent infringement litigation; decision could provide guidance on drug delivery system patent listability: King Pharmaceuticals v Intelliject (FDA Law Blog)

Fentora (Fentanyl) – US: Cephalon files patent infringement complaint against Mylan in response to Para IV filing (Patent Docs)

Melatonin – EU: EWCA refers SPC questions to the ECJ: Neurim Pharmaceuticals (1991) Ltd v Comptroller General of Patents (The SPC Blog) (The SPC Blog) (EPLAW) (IPKat)

Olmesartan medoxomil / Hydrochlorothiazide – EU: Daiichi questions now on Curia (The SPC Blog)

Restasis (Ciclosporin) – US: Marking with an unexpired patent not fixed by also marking with a live patent: Simonian v. Allergan, Inc (Chicago IP Litigation Blog)

Synagis (Palivizumab) – US: PDL BioPharma settles Medimmune Synagis litigation for $93M (Patent Docs)

TriCor (Fenofibrate) – US: Abbott and Elan end TriCor suit with Ranbaxy (Patent Docs)

Valsartan – Norway: Oslo District Court holds Actavis’ Valsartan/HCTZ product infringes Novartis’ patent covering synthesis route for Valsartan; deals inter alia with scope of Valsartan SPC (The SPC Blog)